Search

Author/Creator Abraham, Prema

1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Issue 10326 (19th February 2022)

Authors:
Heier, Jeffrey S; Khanani, Arshad M; Quezada Ruiz, Carlos; Basu, Karen; Ferrone, Philip J; Brittain, Christopher; Figueroa, Marta S; Lin, Hugh; Holz, Frank G; Patel, Vaibhavi; Lai, Timothy Y Y; Silverman, David; Regillo, Carl; Swaminathan, Balakumar; Viola, Francesco; Cheung, Chui Ming Gemmy; Won...
Journal:
Lancet
Issue:
Volume 399:Issue 10326(2022)
Page Start:
729
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Issue 10326 (19th February 2022)

Authors:
Wykoff, Charles C; Abreu, Francis; Adamis, Anthony P; Basu, Karen; Eichenbaum, David A; Haskova, Zdenka; Lin, Hugh; Loewenstein, Anat; Mohan, Shaun; Pearce, Ian A; Sakamoto, Taiji; Schlottmann, Patricio G; Silverman, David; Sun, Jennifer K; Wells, John A; Willis, Jeffrey R; Tadayoni, Ramin; Aaber...
Journal:
Lancet
Issue:
Volume 399:Issue 10326(2022)
Page Start:
741
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. TYPE 1 VERSUS TYPE 3 NEOVASCULARIZATION IN PIGMENT EPITHELIAL DETACHMENTS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: A Prospective Study. (December 2016)

Authors:
Chen, Xuejing; Al-Sheikh, Mayss; Chan, Clement K.; Hariri, Amir H.; Abraham, Prema; Lalezary, Maziar; Lin, Steven G.; Sadda, SriniVas; Sarraf, David
Journal:
Retina
Issue:
Volume 36(2016)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗